# EDGAR Filing Document

**Accession Number:** 0001792746
**File Stem:** 0001209191-23-000879
**Filing Date:** 2023-1
**Character Count:** 7617
**Document Hash:** 4ecbfbd2824d1eda253aec05fb87cb4d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-000879.hdr.sgml**: 20230104

**ACCESSION NUMBER**: 0001209191-23-000879

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20221230

**FILED AS OF DATE**: 20230104

**DATE AS OF CHANGE**: 20230104

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Pasternak Andy
- **CENTRAL INDEX KEY:** 0001792746

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35238
- **FILM NUMBER:** 23506540

**MAIL ADDRESS:**
- **STREET 1:** C/O HORIZON THERAPEUTICS PLC
- **STREET 2:** CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD
- **CITY:** DUBLIN
- **STATE:** L2
- **ZIP:** D04 C5Y6
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Horizon Therapeutics Public Ltd Co
- **CENTRAL INDEX KEY:** 0001492426
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** CONNAUGHT HOUSE, 1ST FLOOR
- **STREET 2:** 1 BURLINGTON ROAD
- **CITY:** DUBLIN
- **STATE:** L2
- **ZIP:** 4
- **BUSINESS PHONE:** 011-353-1-772-2100

**MAIL ADDRESS:**
- **STREET 1:** CONNAUGHT HOUSE, 1ST FLOOR
- **STREET 2:** 1 BURLINGTON ROAD
- **CITY:** DUBLIN
- **STATE:** L2
- **ZIP:** 4

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Horizon Pharma plc
- **DATE OF NAME CHANGE:** 20140919

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HORIZON PHARMA, INC.
- **DATE OF NAME CHANGE:** 20100520

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Pasternak Andy<br><sub>(Last) (First) (Middle)</sub><br>C/O HORIZON THERAPEUTICS PLC,<br>70 ST. STEPHEN?S GREEN<br><sub>(Street)</sub><br>DUBLIN, L2 D02 E2X4<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2022-12-30 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_EVP, Chief Strategy Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Horizon Therapeutics Public Ltd Co [ HZNP ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 2022-12-30 |  | M |  | 88733 | A | <sup>(1)</sup> | 122780 | D |  |
| Ordinary Shares | 2022-12-30 |  | F |  | 39313 | D | $113.80 | 83467 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Performance Restricted Stock Units (PSU) | <sup>(1)</sup> | 2022-12-30 |  | M |  |  | 8709 | <sup>(2)</sup> | <sup>(2)</sup> | Ordinary Shares | 8709 | $0.00 | 0 | D |  |
| Performance Restricted Stock Units (PSU) | <sup>(1)</sup> | 2022-12-30 |  | M |  |  | 2360 | <sup>(2)</sup> | <sup>(2)</sup> | Ordinary Shares | 2360 | $0.00 | 0 | D |  |
| Performance Restricted Stock Units (PSU) | <sup>(1)</sup> | 2022-12-30 |  | M |  |  | 5800 | <sup>(2)</sup> | <sup>(2)</sup> | Ordinary Shares | 5800 | $0.00 | 0 | D |  |
| Performance Restricted Stock Units (PSU) | <sup>(1)</sup> | 2022-12-30 |  | M |  |  | 26124 | <sup>(2)</sup> | <sup>(2)</sup> | Ordinary Shares | 26124 | $0.00 | 0 | D |  |
| Performance Restricted Stock Units (PSU) | <sup>(1)</sup> | 2022-12-30 |  | M |  |  | 11648 | <sup>(3)</sup> | <sup>(3)</sup> | Ordinary Shares | 11648 | $0.00 | 5816 | D |  |
| Restricted Stock Units (RSU) | <sup>(1)</sup> | 2022-12-30 |  | M |  |  | 14514 | <sup>(2)</sup> | <sup>(2)</sup> | Ordinary Shares | 14514 | $0.00 | 0 | D |  |
| Restricted Stock Units (RSU) | <sup>(1)</sup> | 2022-12-30 |  | M |  |  | 11643 | <sup>(3)</sup> | <sup>(3)</sup> | Ordinary Shares | 11643 | $0.00 | 11643 | D |  |
| Restricted Stock Units (RSU) | <sup>(1)</sup> | 2022-12-30 |  | M |  |  | 7935 | <sup>(4)</sup> | <sup>(4)</sup> | Ordinary Shares | 7935 | $0.00 | 15870 | D |  |

---

### Footnotes:

(1) Each PSU/RSU represents a contingent right to receive one ordinary share of the Issuer.

(2) The final tranche of ordinary shares subject to the PSU/RSU vested on December 30, 2022.

(3) The remaining ordinary shares subject to the PSU/RSU vest on January 5, 2024.

(4) The remaining ordinary shares subject to the RSU vest ratably on January 5, 2024 and January 5, 2025.

**Signature:** /s/ Patrick McIlvenny, Attorney-in-Fact  
**Date:** 2023-01-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**